Exclusive Summary

• Differentiated Prodrug Design: UB020 is a PD-1 targeting IL-15 prodrug featuring a tumor-specific protease-cleavable mask. It demonstrates a >3000-fold reduction in potency in peripheral circulation, effectively mitigating the systemic toxicity issues associated with traditional cytokine therapies.
• Superior PK and Safety Profile: Incorporating an anti-HSA domain, it achieves an extended half-life of 6-10 days in cynomolgus monkeys. The drug was well-tolerated at 10 mg/kg in repeat-dose toxicity studies, suggesting a Best-in-Class safety potential.
• Synergistic Anti-Tumor Mechanism: By combining PD-1 targeting with IL-15 'cis-activation,' UB020 specifically stimulates intratumoral CD8+ T cells and NK cells, delivering robust tumor growth inhibition and immune modulation in preclinical models.

Asset Materials

Contact Us for Full Materials